Thursday, January 07, 2021 6:30:52 AM
Collegium Pharmaceutical, Inc.
Wed, January 6, 2021, 4:01 PM EST
– Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million –
– Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million –
– Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million –
STOUGHTON, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance.
“Collegium achieved a financially transformative year in 2020, driven by Xtampza ER growth and the acquisition of the Nucynta franchise. We delivered on our broad operational objectives and prioritized the health and safety of our people, customers and the communities that we serve,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “As we head into 2021, we remain steadfast in our commitment to being the leader in responsible pain management, maximizing the potential of our differentiated pain portfolio and creating value for our shareholders.”
“Our 2021 revenue outlook is supported by Xtampza ER growth, stable profit contribution from the Nucynta franchise and a commitment to leverage our cost structure,” said Paul Brannelly, Executive Vice President and Chief Financial Officer of Collegium. “This year, we expect to generate significant cash flow from operations and will deploy our balance sheet in a disciplined manner that invests in the long-term growth of our company.”
Financial Guidance for 2021
Xtampza® ER revenues are expected in the range of $155.0 million to $165.0 million
Nucynta® franchise revenues are expected in the range of $175.0 million to $185.0 million
Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $160.0 million to $170.0 million
Total operating expenses are expected in the range of $125.0 million to $135.0 million
https://finance.yahoo.com/news/collegium-provides-2021-financial-guidance-210100747.html
Recent COLL News
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:26:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 10:24:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:39:36 PM
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 02/22/2024 09:09:56 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:03:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:15:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:14:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:13:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:04:28 PM
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:19:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 09:20:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 01:03:11 PM
- Collegium Provides 2024 Financial Guidance • GlobeNewswire Inc. • 01/03/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:36:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/21/2023 09:15:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 10:51:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/20/2023 09:28:33 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM